scholarly journals Processed Food Additive Microbial Transglutaminase and Its Cross-Linked Gliadin Complexes Are Potential Public Health Concerns in Celiac Disease

2020 ◽  
Vol 21 (3) ◽  
pp. 1127 ◽  
Author(s):  
Aaron Lerner ◽  
Torsten Matthias
Keyword(s):  
Celiac Disease ◽  
Tissue Transglutaminase ◽  
Microbial Transglutaminase ◽  
Processed Food ◽  
The Public ◽  
Food Industries ◽  
Survival Factor ◽  
Gliadin Peptide ◽  
Wheat Products ◽  
Potential Public Health

Microbial transglutaminase (mTG) is a survival factor for microbes, but yeasts, fungi, and plants also produce transglutaminase. mTG is a cross-linker that is heavily consumed as a protein glue in multiple processed food industries. According to the manufacturers’ claims, microbial transglutaminase and its cross-linked products are safe, i.e., nonallergenic, nonimmunogenic, and nonpathogenic. The regulatory authorities declare it as “generally recognized as safe” for public users. However, scientific observations are accumulating concerning its undesirable effects on human health. Functionally, mTG imitates its family member, tissue transglutaminase, which is the autoantigen of celiac disease. Both these transglutaminases mediate cross-linked complexes, which are immunogenic in celiac patients. The enzyme enhances intestinal permeability, suppresses mechanical (mucus) and immunological (anti phagocytic) enteric protective barriers, stimulates luminal bacterial growth, and augments the uptake of gliadin peptide. mTG and gliadin molecules are cotranscytosed through the enterocytes and deposited subepithelially. Moreover, mucosal dendritic cell surface transglutaminase induces gliadin endocytosis, and the enzyme-treated wheat products are immunoreactive in CD patients. The present review summarizes and updates the potentially detrimental effects of mTG, aiming to stimulate scientific and regulatory debates on its safety, to protect the public from the enzyme’s unwanted effects.

scholarly journals THE USEFULNESS OF DEAMIDATED GLIADIN PEPTIDE IN SCREENING PEDIATRIC PATIENTS FOR CELIAC DISEASE

2018 ◽  
Vol 23 (suppl_1) ◽  
pp. e14-e14
Author(s):  
Michelle Gould ◽  
Herbert Brill ◽  
Margaret Marcon ◽  
Catharine Walsh
Keyword(s):  
Celiac Disease ◽  
Positive Predictive Value ◽  
Predictive Value ◽  
Tissue Transglutaminase ◽  
Paediatric Population ◽  
Iga Deficiency ◽  
Additional Patient ◽  
Serologic Marker ◽  
Paediatric Patients ◽  
Gliadin Peptide

Abstract BACKGROUND Celiac disease (CD) is an autoimmune enteropathy triggered by gliadin. The gold standard for diagnosis is small bowel biopsy. Screening with serologic markers to identify endoscopic candidates is commonly completed by paediatricians. The most common serologic marker used for screening is IgA anti-Tissue Transglutaminase (TTG) antibodies. Antibodies to deamidated gliadin peptide (DGP) is a newer assay with studies demonstrating a diagnostic performance similar to anti-TTG. In Canada, this assay has been added to many laboratory’s celiac screening panels. There is little evidence however regarding the usefulness of an isolated positive anti-DGP result in paediatric patients and no study has systematically assessed the presence of biopsy proven CD in solely anti-DGP positive paediatric patients. OBJECTIVES We sought to determine the positive predictive value of anti-DGP for biopsy proven CD in paediatric patients with negative TTG IgA testing. DESIGN/METHODS A multi-center retrospective review of children referred to three centers in Ontario, Canada between January 2015 and December 2016 who had isolated anti-IgG DGP positive CD serology was completed. To be included, patients required serology positive for DGP IgG and negative for all other celiac serologic tests, as well as a duodenal biopsy while on a gluten-containing diet. The positive predictive value of isolated anti-DGP was calculated. RESULTS A total of 83 patients were identified with anti-DGP positive, anti-TTG negative serology. Of these, 40 patients underwent endoscopy. Only 1 patient had findings consistent with CD on biopsy (Marsh 3B histology), yielding a positive predictive value of 2.5%. This patient was IgA deficient. Amongst the cohort of IgA sufficient patients (N=25), the positive predictive value of anti-DGP serology was 0%. One additional patient who was IgA sufficient had findings in keeping with Marsh 2 histology, but repeat TTG and DGP testing was negative. Five patients were found to be IgA deficient at the time of serologic testing, 25 were IgA sufficient and 10 did not have a measured IgA. CONCLUSION Isolated positive DGP IgG serology has a poor positive predictive value for CD, especially in IgA sufficient individuals. For this reason, DGP IgG testing should not be completed as part of the initial screening for celiac disease in the paediatric population unless a compelling reason, such as IgA deficiency or age under 2 years, is present, in order to prevent unnecessary invasive follow-up testing and costs to patients and the health care system.

scholarly journals Blocking celiac antigenicity of the glutamine-rich gliadin 33-mer peptide by microbial transglutaminase

RSC Advances ◽  
2017 ◽  
Vol 7 (24) ◽  
pp. 14438-14447 ◽  
Author(s):  
Lin Zhou ◽  
Yujie Wu ◽  
Youfei Cheng ◽  
Jie Wang ◽  
Jun Lu ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Microbial Transglutaminase ◽  
Acyl Acceptor ◽  
Gliadin Peptide

Transamidation by mTG with variety of acyl-acceptor substrates decreased the antigenicity of gliadin peptide related to celiac disease.

scholarly journals Testing for Antireticulin Antibodies in Patients with Celiac Disease Is Obsolete: a Review of Recommendations for Serologic Screening and the Literature

2013 ◽  
Vol 20 (4) ◽  
pp. 447-451 ◽  
Author(s):  
Sarada L. Nandiwada ◽  
Anne E. Tebo
Keyword(s):  
Celiac Disease ◽  
Tissue Transglutaminase ◽  
Clinical Manifestations ◽  
Autoimmune Disorder ◽  
Diagnostic Use ◽  
Gliadin Peptide ◽  
Gluten Sensitive Enteropathy ◽  
Serologic Screening ◽  
Related Proteins ◽  
Hla Dq2

ABSTRACTCeliac disease (CD) is an autoimmune disorder that occurs in genetically susceptible individuals of all ages and is triggered by immune response to gluten and related proteins. The disease is characterized by the presence of HLA-DQ2 and/or -DQ8 haplotypes, diverse clinical manifestations, gluten-sensitive enteropathy, and production of several autoantibodies of which endomysial, tissue transglutaminase, and deamidated gliadin peptide antibodies are considered specific. Although antireticulin antibodies (ARA) have historically been used in the evaluation of CD, these assays lack optimal sensitivities and specificities for routine diagnostic use. This minireview highlights the advances in CD-specific serologic testing and the rationale for eliminating ARA from CD evaluation consistent with recommendations for diagnosis.

scholarly journals Microbial Transglutaminase Is a Very Frequently Used Food Additive and Is a Potential Inducer of Autoimmune/Neurodegenerative Diseases

Toxics ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 233
Author(s):  
Aaron Lerner ◽  
Carina Benzvi
Keyword(s):  
Immune Cells ◽  
Posttranslational Modification ◽  
Scientific Community ◽  
Microbial Growth ◽  
Tissue Transglutaminase ◽  
Food Additive ◽  
Microbial Transglutaminase ◽  
The Public ◽  
Gluten Enteropathy ◽  
Gliadin Peptides

Microbial transglutaminase (mTG) is a heavily used food additive and its industrial transamidated complexes usage is rising rapidly. It was classified as a processing aid and was granted the GRAS (generally recognized as safe) definition, thus escaping full and thorough toxic and safety evaluations. Despite the manufacturers claims, mTG or its cross-linked compounds are immunogenic, pathogenic, proinflammatory, allergenic and toxic, and pose a risk to public health. The enzyme is a member of the transglutaminase family and imitates the posttranslational modification of gluten, by the tissue transglutaminase, which is the autoantigen of celiac disease. The deamidated and transamidated gliadin peptides lose their tolerance and induce the gluten enteropathy. Microbial transglutaminase and its complexes increase intestinal permeability, suppresses enteric protective pathways, enhances microbial growth and gliadin peptide’s epithelial uptake and can transcytose intra-enterocytically to face the sub-epithelial immune cells. The present review updates on the potentially detrimental side effects of mTG, aiming to interest the scientific community, induce food regulatory authorities’ debates on its safety, and protect the public from the mTG unwanted effects.

scholarly journals Positive Deamidated Gliadin Peptide Antibodies and Negative Tissue Transglutaminase IgA Antibodies in a Pediatric Population: To Biopsy or Not To Biopsy

2010 ◽  
Vol 17 (5) ◽  
pp. 884-886 ◽  
Author(s):  
Miriam Parizade ◽  
Bracha Shainberg
Keyword(s):  
Celiac Disease ◽  
Clinical Laboratory ◽  
Tissue Transglutaminase ◽  
Pediatric Population ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Negative Results ◽  
Iga Antibodies ◽  
Gliadin Peptide ◽  
Peptide Antibodies

ABSTRACT Reports from our clinical laboratory database show that 75% of children <2 years old tested for celiac serology who were found positive for deamidated gliadin peptide (DGP) antibodies had negative results for tissue transglutaminase IgA. DGP levels were shown to decline and disappear without a gluten-free diet. This observation questions DGP's specificity for diagnosis of celiac disease.

Sign in / Sign up

Export Citation Format

Share Document